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Context: Mouse studies suggest that adropin, a peptide hormone, is required for metabolic ho-
meostasis and prevention of obesity-associated insulin resistance. Whether obesity and insulin
resistance are associated with low plasma adropin levels in humans is not known.
Objectives: Our objective was to investigate the hypothesis that obesity and indicators of insulin
resistance are associated with low adropin levels and determine whether weight loss regulates
adropin levels.
DesignandParticipants:Plasmawasobtained from85 female [age21–67 yr, bodymass index (BMI)
19.4–71.5 kg/m2] and 45 male (age 18–70 yr, BMI 19.1–62.6 kg/m2) volunteers for other clinical
studies. The impact of Roux-en-Y gastric bypass was investigated in 19 obese females (BMI 37–65
kg/m2) using samples collected at baseline and 1–12 months after surgery.
Results:Adropin levels correlate negatively with BMI (r0.335, P 0.001) and age (r0.263,
P0.003). Age-adjusted adropin levels are higher in males [4.1 ng/ml; 95% confidence interval
(CI) 3.6–4.6 ng/ml] than females (3.0 ng/ml; 95% CI 2.6–3.4 ng/ml) (P 0.001). In all subjects,
lowerage-adjustedadropin levelswereobserved inoverweight (3.3ng/ml; 95%CI2.8–3.8ng/ml,
P 0.033) and obese (2.7 ng/ml; 95%CI 2.1–3.3 ng/ml, P 0.001) comparedwith healthy-weight
subjects (4.1 ng/ml; 95% CI  3.6–4.5 ng/ml). This effect was gender specific (weight category 
gender, P  0.001) and was observed in males only. Aging and diagnosis with two or more met-
abolic syndrome risk factors was associated with low adropin levels, irrespective of sex. Adropin
concentrations increasedafterRoux-en-Ygastric bypass, peaking3months after surgery (P0.01).
Conclusions:Althoughmales exhibit higher adropin levels that are reduced by obesity, aging and
markers of insulin resistance are associated with low plasma adropin irrespective of sex. (J Clin
Endocrinol Metab 97: 3783–3791, 2012)
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acids; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin
resistance; HOMA-B, assessment of -cell function; LDL, low-density lipoprotein; MSRF,
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Adropin, first described in 2008, is a peptide hormoneencoded by the energy homeostasis-associated
(ENHO) gene (1). The adropin open reading frame is
unique and produces a small 76-residue secreted peptide
that is very highly conserved (97–100%) in the genomes of
eutherian (placental) mammals. The adropin transcript is
abundant in liver (1), and in mice hepatic expression and
circulating adropin concentrations both exhibit rapid reg-
ulation by fasting (inhibition) and refeeding (stimulation),
suggesting regulation by signals of metabolic status (1, 2).
Studies inmousemodels of obesity and cell-based systems
strongly suggest that adropin is involved in metabolic ho-
meostasis and cardiovascular function (1–4). Impor-
tantly, in mice, diet-induced and genetically induced obe-
sity is associatedwith decreased expression of the adropin
transcript in liver and in circulating adropin concentra-
tions (1, 2). A decline in adropin action with obesity may
therefore contribute to the development of insulin resistance
and dyslipidemia. Supporting this hypothesis, adropin-
knockout mice exhibit increased adiposity and fasting trig-
lycerides (TG), hepatic steatosis, insulin resistance, and in-
creased propensity for impaired glucose tolerance with diet-
induced obesity (2).
Based on these observations, we hypothesize that low
adropin levels may be a risk factor for the development of
insulin resistance and other features of the metabolic syn-
drome such as dyslipidemia that are associated with obe-
sity. To date, only one study has examined circulating
adropin concentrations in humans, reporting increased
serumadropin levels in aged subjects (60–92 yr)with end-
stage heart failure (3). Whether low adropin levels corre-
late with obesity and insulin resistance in humans has not
been investigated. The aim of the current study was there-
fore to investigate the impact of obesity, metabolic status,
and weight loss after bariatric surgery on plasma adropin
concentrations in humans. However, as adropin exhibits
regulation by food intake inmice (1, 2), we also examined
whether plasma adropin levels are regulated by meal in-
take inhumans.However, as adropin levels didnot exhibit
regulation by feeding, we used fasting samples to compare
adropin levels in lean and obese subjects. Collectively, our
data suggest that adropin levels are low in obesity and that
metabolic risk factors such as dyslipidemia may also be
associated with low adropin levels.
Subjects and Methods
Adropin levels were measured in plasma samples obtained from
volunteers for five studies performed at the Pennington Biomed-
ical Research Center (PBRC) (Baton Rouge, LA), the New York
Obesity Nutrition Research Center (NYONRC) (St. Luke’s-
Roosevelt Hospital Center, New York, NY) and the University
ofCalifornia (UC)DavisClinical andTranslational ScienceCen-
ter Clinical ResearchCenter (CCRC). The studieswere reviewed
and approved by the Institutional Review Boards of the PBRC,
St. Luke’s-Roosevelt Hospital Center, and UCDavis. All partic-
ipants provided written informed consent to participate. Age,
body mass index (BMI), and blood chemistry data (when avail-
able) for these subjects grouped by study are shown in Table 1.
The use of medications for dyslipidemia or hypertension was an
exclusion criterion for these studies.
Study A (NYONRC)
Plasma adropin was measured in samples obtained from 12
lean female volunteers (four Caucasians, four Hispanic, two Af-
rican-Americans, oneAsian, andonemixed race) for an inpatient
study investigating the effects of sleep onmetabolic homeostasis
(5). The samples used for the current study had been collected at
0800, 0815, 0830, 0900, and 0930 h; every 2 h from 1000–
22-00 h; and at 0730 h the next day. Meals supplying 30% of
resting energy requirement (30% fat, 15% protein, 55% carbo-
hydrates) were served at 0800, 1200, and 1900 h; a snack sup-
plying 10% was given at 1600 h.
Study B (PBRC)
These samples were taken from a larger clinical trial compar-
ing the impact of three bariatric surgery procedures with a low-
calorie diet on insulin sensitivity and energy expenditure
(BARIA, www.ClinicalTrials.gov identifier NCT00936130).
Samples from age-, sex-, and ethnicity-matched lean controls
were collected specifically for the current study. The samples
used for this study were from eight morbidly obese (BMI 
52.2 4.6 kg/m2, age 44.8 3.6 yr) and eight age-, sex- (two
males, six females), and ethnicity-matched (four Caucasians,
TABLE 1. Gender, age, BMI, lipids, insulin, and glucose data for the study subjects
Study (center) Sex n Age (yr)
BMI
(kg/m2)
Blood chemistry
TG
(mg/dl)
FFA
(mEq/liter)
Total cholesterol
(mg/dl)
HDL
(mg/dl)
LDL
(mg/dl)
ApoA1
(mg/dl)
ApoB
(mg/dl)
Insulin
(ng/ml)
Glucose
(mg/dl)
A (NYONRC) Female 12 33.8  1.3 22.7  0.3
B (PBRC) Female 12 41.8  2.5 37.7  5.2
Male 4 49.5  6.1 38.8  8.9
C (UCD-CCRC) Female 21 29.2  1.4 26.8  1.0 102  10 0.38  0.03 165  5 52  3 87  5 131  5 71  4 19  3 88  2
Male 25 26.8  1.5 24.6  0.6 115  8 0.32  0.03 157  7 43  2 91  6 117  3 73  5 16  1 89  1
D (UCD-CCRC) Female 16 54.4  1.5 29.9  0.8 152  19 0.44  0.04 195  8 41  2 124  9 131  7 82  7 15  2 89  1
Male 15 53.1  2.5 28.6  0.6 138  17 0.33  0.02 177  7 37  3 115  5 122  8 80  5 14  2 87  1
E (UCD-CCRC) Female 24 42.2  1.8 45.8  1.3 123  28 0.28  0.03 178  8 42  2 104  8 155  6 111  7 29  3 99  5
Data are mean  SEM.
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fourAfrican-Americans) lean subjects (BMI23.70.6 kg/m2,
age  42.6  3.6 yr). Blood samples were collected at baseline
(fasting) [time 15 min) (t15)] and 60 (t60) and 120 (t120)
minutes after a 400-kcal liquid breakfast (40%fat, 20%protein,
40% carbohydrates).
Study C (UC Davis CCRC)
Baseline samples were obtained from 27 male and 21 female
volunteers (32Caucasian, fiveHispanic, fourAfrican-American,
four Asian, one Native American, and two Asian/Pacific Is-
lander) for a clinical study investigating the effect of dietary sug-
ars on insulin resistance and lipidmetabolismover a 2-wkperiod
(6, 7). For this study, we used baseline samples that had been
collected at 0800, 0830, and 0900 h after an overnight fast and
then pooled. Samples collected at 2200, 2300, and 2400 h, the
period of peak TG concentrations, were used to assess adropin
levels during the postabsorptive phase.
Study D (UC Davis, CCRC)
Samples were obtained from 15 male and 16 female volun-
teers (23 Caucasians, five Hispanic, and three Asian) in a study
investigating the impact of dietary sugars on metabolic risk fac-
torsovera10-wkperiod (7).The samplesused for this studywere
baseline samples that had been collected at 0800, 0830, and
0900 h after an overnight fast.
Study E (UC Davis, CCRC)
These samples had previously been collected from a clinical
study of the response of 19 morbidly obese Caucasian females
after Roux-en-Y gastric bypass (RYGB) surgery. The samples
used for this study had been collected after an overnight fast at
baseline and 1, 3, 6, and 12 months after surgery. Study design
and a description of the anthropometric, metabolic, and endo-
crine responses in these patients have been reported previously
(8–10).
Adropin measurements
Serum or plasma adropin was measured in duplicate using a
commercially availableELISA (PeninsulaLaboratories, Bachem,
San Carlos, CA). The samples used had never been previously
thawed. There is 100% conservation of the amino sequence of
human and mouse adropin (1), and the assay detects immuno-
reactivity in bothmouse and human plasma.We previously used
plasma from wild-type and adropin-deficient knockout mice to
test for assay specificity; adropin immunoreactivity was not de-
tected in plasma obtained from adropin-knockout mice (2). We
also spiked human plasmawith synthetic adropin34–76 (Phoenix
Pharmaceuticals, Inc., Burlingame, CA) using a range of con-
centrations (2.8–27.0 ng/ml), observing a linear rate of recovery
(r2  0.9957 between observed and predicted concentration of
adropin) and a recovery rate of more than 100%. The lowest
detection limit was 0.2 ng/ml; the intraassay coefficient of vari-
ation (CV)determinedusingquality-control humanplasma sam-
ples with adropin values ranging from 1.1–2.4 ng/ml was 8.6%,
whereas the interassay CV varied between 19% (PBRC) and
29.6% (UC Davis). We also calculated the CV of the duplicate
samples in the low (0.5–2.5 ng/ml, CV  8.9%), mid (2.5–4.5
ng/ml, CV  6.7%), and high (4.5–22.0 ng/ml, CV  5.1%)
ranges.
Study A samples were collected in EDTA-coated tubes with a
dipeptidyl peptidase-4 inhibitor and aprotinin. Samples for
study B were collected with a protease inhibitor cocktail (Roche
Diagnostics,Dallas,TX;MilliporeCorp,Bedford,MA) thatpro-
vides a broad spectrum of protease inhibition that is used to
avoid possible interference from EDTA. For studies C–E, sam-
ples were collected in EDTA tubes.
Associations between plasma adropin and
metabolic risk factors
Data available from studies C–E included plasma lipids [TG,
free fatty acids (FFA), total cholesterol, low-density lipoprotein
(LDL), high-density lipoprotein (HDL), apolipoproteins (Apo)B
and A1], glucose, insulin, and blood pressure (6–13). The met-
abolic syndrome risk factor (MSRF) score (a numerical score of
the number of facets of the metabolic syndrome) was calculated
by scoring each subject a value of 1 for fasting TG at least 150
mg/dl, HDL no higher than 40 mg/dl for males or 49 mg/dl for
females, waist circumference at least 102 cm for males or 88 cm
for females, fasting glucose at least 100mg/dl, and systolic blood
pressure at least 130 mmHg or diastolic blood pressure at least
85mmHg. The criteria used forMSRF score were those defined
by the American Heart Association/National Heart, Lung, and
Blood Institute (14–16).
Statistical analysis
Data were analyzed using SPSS version 19. Correlations
between adropin and anthropomorphic and blood chemistry
data were assessed using the Pearson product-moment corre-
lation coefficient (r) and multiple regression. Adropin levels
over the daywere analyzed using repeated-measures ANOVA.
The effects of study and gender on plasma adropin levels were
assessed using a multivariate ANOVA using normal or trans-
formed data with Bonferroni correction for post hoc compar-
isons. In situations where Levene’s test of equality of error
variances indicated unequal variance between groups, data
transformation was employed. In situations where data trans-
formation failed to produce equal variance, nonparametric
tests were used (Kruskal-Wallis ANOVA). Unless stated oth-
erwise, data are presented as mean  SEM.
Results
Plasma adropin levels do not exhibit meal- or
circadian-related changes
Plasmaadropin levels inmice exhibit regulationby fast-
ing and refeeding (1, 2). We therefore measured adropin
FIG. 1. Meal intake and overnight fasting have no significant effect on
plasma adropin levels in female volunteers. Plasma adropin levels were
measured throughout the day and after an overnight fast. Meal times
are indicated by letters (B, breakfast; L, lunch; S, snack; D, dinner).
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levels throughout the daytime to determine whether it is
regulatedbymeal- or circadian-related factors. In healthy-
weight females, plasma adropin levels did not exhibit
meal- or circadian-related changes (study A, Fig. 1). In
study B, adropin levels did not change 60 and 120 min
after breakfast in healthy-weight subjects (t15, 2.6 0.4;
t60, 2.7 0.4; t120, 2.7 0.4 ng/ml) or obese subjects
(t15, 2.2  0.3; t60, 2.3  0.3; t120, 2.0  0.3 ng/ml)
(time effect, P  0.838; body weight effect, P  0.290;
interaction between time and body weight, P  0.392).
Adropin levels alsodidnotdifferbetween fastingandpost-
prandial conditions in study C (4.2  0.3 vs. 4.3  0.2
ng/ml, respectively, P  0.332).
These data suggest that levels of adropin in plasma are
stable over time and do not exhibit marked diurnal or
meal-related variations. Studies examining the impact of
obesity on plasma adropin levels
therefore used samples collected
after an overnight fast.
Decreased adropin
concentrations with high
BMI and aging
In pooled samples from stud-
ies A–E (n  130), a significant
negative association between
BMI and fasting adropin concen-
trations was observed (r 
0.335,P0.001,Fig. 2A). Sig-
nificant associations between
adropin concentrations and BMI
were observed when males (r 
0.318, P 0.033, n 45) and
females (r0.291, P 0.007,
n  85) were analyzed indepen-
dently, although for females, the
decline with obesity was less se-
vere. Analysis of the impact of
ethnicitywith age andBMIas co-
variates indicated no significant
effect (P  0.423).
Subjects were then catego-
rized as healthy body weight
(BMI  18.5–24.9 kg/m2, n 
41); overweight (BMI25–29.9
kg/m2, n 35), or obese (BMI
30 kg/m2, n  54). Because age
significantly affected adropin
levels (Fig. 2B), age-adjusted
plasma adropin levels were used
for the analysis. Adropin levels
were lower in the overweight
(3.4 ng/ml; 95% CI  2.8–4.0
ng/ml) and obese groups (3.1 ng/ml; 95% CI  2.5–3.7
ng/ml) comparedwith healthy-weight subjects (4.1 ng/ml;
95%CI 3.6–4.7 ng/ml) (Fig. 2C).When analyzed using
gender and weight category as fixed factors and age as a
covariate, the effect of weight did not achieve statistical
significance (P 0.060).However, therewas a significant
effect of gender (P  0.001) and a significant interaction
betweengender andweight category (P0.005).Adropin
levels were higher in males (4.1 ng/ml; 95%CI 3.6–4.6
ng/ml) than females (3.0 ng/ml; 95%CI2.6–3.4 ng/ml).
When analyzed separately, therewas a significant effect of
weight category inmales (P 0.024) but not females (P
0.127). Adropin levels were lower (P  0.021) in over-
weight (3.3 ng/ml; 95% CI  2.5–4.2 ng/ml, n  24)
compared with healthy-weight males (5.6 ng/ml; 95%
FIG. 2. Analysis of the impact of obesity and aging on plasma adropin levels in males and females. A,
Plasma adropin levels as a function of BMI; B, plasma adropin levels as a function of age; C, age-
adjusted plasma adropin levels in subjects categorized as being of healthy weight (BMI  18.5–24.9
kg/m2), overweight (BMI  25–29.9 kg/m2), or obese (BMI  30 kg/m2). Multivariate analysis
indicated that the effect of obesity is sex specific. There was a significant effect of gender (P  0.05),
with higher levels in males (plasma adropin levels  3.7  0.2 ng/ml) relative to females (3.0  0.2
ng/ml). Significance (*, P  0.05; **, P  0.01) was determined using Bonferroni post hoc analysis.
D, BMI-adjusted plasma adropin levels by age group. The difference between those under 30, 40–50,
and 50 yr and older was significant in all subjects (*, P  0.05 vs. 30 yr by post hoc analysis using
Bonferroni’s analysis). There was a trend (P  0.058) for an effect of gender on plasma adropin levels.
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CI  4.3–6.9 ng/ml, n  13). There was no significant
difference between healthy-weight and obese males (3.5
ng/ml; 95% CI  2.0–5.0 ng/ml, n  8, P  0.169).
Two outliers were observed in the overweight and
obese males. A subject with a BMI of 29.1 kg/m2 had an
adropin concentration of 9.3 ng/ml (6.5 SD from the av-
erage). Another subject with BMI of 31.7 kg/m2 had an
adropin value of 10.0 ng/ml (8.4 SD from the average).
Excluding these subjects led to the weight-category effect
achieving significance in all subjects (P  0.020); gender
(P  0.031) and the interaction between gender and
weight category (P  0.003) were still significant. When
males were analyzed separately, age-adjusted adropin lev-
elswere significantly lower in overweight (3.1 ng/ml; 95%
CI  2.5–3.7 ng/ml, n  23, P  0.001) and obese (2.8
ng/ml; 95%CI 1.6–3.9 ng/ml, n 7, P 0.006) males
compared with healthy-weight males (5.4 ng/ml, 95%
CI  4.5–6.3 ng/ml, n  13) (Fig. 2C).
Adropin levels decreased with age (Fig. 2B), with a sig-
nificant negative association between plasma adropin lev-
els and age (r  0.251, P  0.004) that was still signif-
icant when controlled for BMI (r  0.195, P  0.027).
Plasma adropin concentrations were then analyzed in
groups categorized as being 30 yr or younger (n  34),
30–40 yr (n 39), 40–50 yr (n 30) or over 50 yr (n
27). Individuals aged 30 yr or younger were grouped to-
gether due to a low number of participants aged under 2
0 yr (five males). Plasma adropin levels are highest in in-
dividuals aged 30 yr or younger (Fig. 2D). Multivariate
analysis with BMI as a covariate indicated significant ef-
fects of age (P 0.050) and gender (P 0.011), with no
interactionbetweengender andage (P0.995).When the
outliers mentioned previously were excluded from the
analysis, age effects remained significant (P  0.007);
however, gender was no longer significant (P  0.058).
To investigate whether age and BMI interact to affect
plasma adropin levels,we performed amultiple regression
analysis using BMI, age, and gender as independent vari-
ables. Inclusion of all three variables produced the stron-
gest association (r 0.454, P 0.001), with the formula
adropin levels  6.008  (0.036  BMI)  (0.026 
age)  (0.959  gender), where gender  0 for males or
1 for females.
Data from an anthropometric analysis (body fat, per-
cent body fat, height, and weight) were also available for
participants of studies C and D (n  45). Participants in
studyDwere nearly twice as old as those in studyC (Table
1). Subjects in study Dwere also more obese because BMI
below 25 kg/m2 was an exclusion criterion for the study.
Partial correlation analysis controlling for age, gender,
and study indicated significant associations between
plasma adropin and BMI (r  0.235, P  0.044) and
adropin and body weight (r0.252, P 0.030) for all
subjects. However, no significant correlations were evi-
dent between adropin and body fat content when age and
gender were controlled for.
Associations between plasma adropin and risk
factors for metabolic disease
We next investigated whether plasma adropin levels
are reduced in subjects with a MSRF score of 1 or more
(Fig. 3A). Analysis of plasma adropin usingMSRF score
and gender as fixed variables and age as a covariate
indicated a significant effect ofMSRF score (P 0.001)
but no effect of gender (P  0.893) and no interaction
between gender andMSRF score (P 0.144).Menwith
a MSRF score of 2 or more had plasma adropin con-
centrations that were 50% lower compared with sub-
jects with noMSRF score (P 0.01). In women, plasma
adropin levels were similar in subjects withMSRF score
FIG. 3. Low plasma adropin levels in individuals with metabolic risk
factors. A, Plasma adropin levels (age-adjusted) in subjects grouped by
MSRF score (0, 1, 2, or more than 3). Significantly different from
MSRF  0 or as indicated: *, P  0.05; **, P  0.01 (post hoc analysis
using Bonferroni’s correction for multiple comparisons). B, Negative
correlation between fasting plasma adropin and fasting TG in males
(shaded circles) and females (open circles). The data used shown in this
analysis are natural log transformed.
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of 0 or 1; however, adropin was lower in subjects with
a MSRF score of 3 or more.
We then examined the relationship between plasma
adropin and individual metabolic risk factors. Plasma lip-
ids (fasting TG, FFA, total cholesterol, HDL, LDL, ApoB,
and ApoA1), measures of glucose homeostasis [fasting in-
sulin, fasting glucose, homeostatic model assessment of
insulin resistance (HOMA-IR) and HOMA-B], and mea-
surements of diastolic and systolic blood pressure were
available for 99 subjects (43 males, 56 females). Partial
correlation analysis controlling for gender found signifi-
cant negative associations between plasma adropin levels
andTG,ApoB,LDL, glucose, andbloodpressure; positive
associations were also observed between plasma adropin
and HDL and FFA (Table 2).
Age and obesity are risk factors for insulin resistance
and other facets of the metabolic syndrome, and both
exhibited a negative correlation with plasma adropin
levels.We therefore repeated the analysis using a partial
correlation controlling for gender, age, and BMI. The
results from this analysis suggest that the interaction
between plasma adropin levels and most indicators of
metabolic risk cannot be dissociated from the effects of
aging and increased BMI. However, the exception was
between plasma adropin and fasting TG (Fig. 3B),
which persisted when and age and BMI were controlled
for (r  0.305, P  0.003). For comparison, an anal-
ysis was performed comparing fasting insulin and TG
levels, because insulin resistance is known to be a risk
factor for dyslipidemia (17, 18). As predicted, a positive
correlation was observed between TG and insulin (r 
0.399, P 0.001), glucose (r 0.497, P 0.001), and
HOMA-IR (r  0.513, P  0.001).
Assay data assessing liver function was available for
study C. Data from mice suggests that the liver may be a
significant source of circulating adropin (1, 2). We there-
fore analyzed whether there was any correlation between
the levels of adropin and transminases in the circulation.
No correlations were observed between plasma adropin
levels and either aspartate aminotransferase (r0.178,
P  0.241), alanine aminotransferase (r  0.123, P 
0.420) or -glutamyl transferase (r0.015, P 0.923)
when age, BMI and sex were controlled for.
Increase in plasma adropin levels after RYGB
RYGB resulted in marked weight loss (Fig. 4A) and
improvements in glucosehomeostasis andblood lipids (8–
10). Plasma adropin concentrations increased after
RYGB, peaking 3 months after surgery (Fig 4B). Despite
continuedweight loss, adropin levels had returned tobase-
line at 12 months. Baseline adropin levels predicted the
decrease in plasma TG after surgery (r  0.631, P 
0.004), likely related to the negative correlation between
adropin levels and TG observed when baseline level of
adropin and TG were analyzed for study E participants
(r  0.462, P  0.047).
Discussion
These data are the first to indicate an association between
lowplasma adropin levelswith obesity and increasedmet-
abolic risk factors in humans. The decline in adropin pro-
TABLE 2. Correlation matrix showing associations
(Pearsons correlation coefficient, r) between plasma
adropin levels and markers of metabolic risk
(dyslipidemia, glucose homeostasis, blood pressure, and
obesity)
r P
Fatty acid metabolism
TG 0.245 0.001
Ln(TG) 0.341 0.001
FFA 0.232 0.029
Ln(FFA) 0.253 0.025
Cholesterol metabolism
Cholesterol 0.179 NS
Ln(cholesterol) 0.218 0.033
HDL 0.258 0.011
Ln(HDL) 0.334 0.001
ApoA1 0.008 NS
Ln(ApoA1) 0.057 NS
ApoB 0.277 0.006
Ln(ApoB) 0.341 0.001
LDL 0.209 0.041
Ln(LDL) 0.165 NS
Glucose homeostasis
Insulin 0.081 NS
Ln(insulin) 0.185 NS
Glucose 0.210 0.040
Ln(glucose) 0.269 0.008
HOMA-IR 0.123 NS
Ln(HOMA-IR) 0.221 0.031
HOMA-B 0.056 NS
Ln(HOMA-B) 0.018. NS
Blood pressure
dBP 0.276 0.006
Ln(dBP) 0.324 0.001
sBP 0.251 0.014
Ln(sBP) 0.274 0.007
Morphometry
BMI 0.371 0.001
Ln(BMI) 0.477 0.001
BW 0.383 0.001
Ln(BW) 0.466 0.001
Age 0.252 0.013
Ln(age) 0.319 0.002
Correlations are shown for raw and natural log (Ln) transformed data
e.g. Ln(adropin) compared with Ln(TG)	. This analysis controlled for
sex; italicized values are not significant. The results shown are from a
partial correlation that controlled for gender. BW, Body weight; dBP,
diastolic blood pressure; NS, not significant; sBP, systolic blood
pressure.
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duction in mouse models of obesity is a secondary conse-
quence of weight gain (1, 2). Whether low adropin levels
in obese humans are also secondary toweight gainwas not
determined in these studies. Plasma adropin levels ranged
from less than 1 to 10 ng/ml in normal-weight subjects. The
loweraverageplasmaadropin level inobese subjectswasdue
to fewer individuals with values in the high end of the range.
Additional studies are required to determine whether low
adropin levelsobserved in thehealthy-weightvolunteerspre-
dict future weight gain or risk of metabolic disorders. How-
ever, results from studies usingmice do not support a major
role for adropin in regulating body weight. Deletion of the
Enho gene encoding adropin inmice has amodest impact on
fat mass but is not associated with hyperphagia or altered
response to diet-induced obesity (2).
Adropin-deficient mice exhibit insulin resistance, dys-
lipidemia, and more pronounced hyperinsulinemia and
impaired glucose tolerance with diet-induced obesity (2).
Moreover, administration of recombinant adropin re-
verses insulin resistance and dyslipidemia in mice (1). In
the current study, we observed a significant negative cor-
relation between plasma adropin and fasting TG concen-
trations after controlling for age and BMI. In addition,
subjects with lower plasma adropin levels exhibited the
largest reductions in plasma TG after RYGB. The associ-
ation between plasma adropin and TG is comparable to
that observed between insulin and TG. Collectively, these
results suggest that, as observed for mice, adropin may
have functions in humans that impact TG metabolism
(synthesis or clearance).
A significant increase in plasma adropin levels was ob-
served after RYGB, suggesting that reversal of the meta-
bolic syndrome associated with obesity is also associated
with a reversal of low plasma adropin levels. However,
weight loss per se does not appear likely to be the main
factor driving the increase, because the response occurred
after significant weight loss had been achieved. The time
of the increase (3 months after surgery) coincides with a
period of dynamic change in metabolic homeostasis. The
initial changes in variables such as blood pressure and
blood chemistries observed 1month after surgery begin to
reverse at this time. Additional studies are needed to in-
vestigate the significance of the change in plasma adropin
that is observed with RYGB and to determine whether
lifestyle-induced weight loss has a similar effect.
Circulating adropin concentrations were also lower in
individuals with a MSRF score of at least 2. This obser-
vation suggests that conditions where the risk of develop-
ingmetabolic diseases is increased are associatedwith low
plasma adropin levels. Additional studies examining
whether low plasma adropin levels are a risk factor for
developing type 2 diabetes and cardiovascular disease are
needed.
In normal-weight individuals, women had lower
plasma adropin levels thanmen. The impact of obesity on
plasma adropin levels was also far less severe in women.
The physiological significance of this gender difference is
unclear at this time. All studies of the role of adropin in
metabolic homeostasis usingmice published thus far have
been conducted inmales (1, 2). Future investigations com-
paring the phenotype of male and female adropin-defi-
cient mice to investigate sex differences may be informa-
tive. Another unanticipated outcome was the decline in
adropin with aging. As with obesity, this effect appeared
to be more pronounced in men (Fig. 1E). If, as data ob-
tained frommouse models suggest, adropin has functions
that are essential for maintaining metabolic homeostasis,
then adeclinewith agemight have been anticipated.Aging
is well known to be associated with deteriorating meta-
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FIG. 4. Gastric bypass surgery is associated with increased plasma
adropin levels in obese females (n  19). A, Impact of gastric bypass
on obesity. All subjects lost weight in the 12 months after surgery. B,
Impact of RYGB on plasma adropin levels. The effect of surgery on
adropin levels was significant (P  0.01), with plasma adropin levels
significantly higher 3 months after surgery relative to levels at baseline
and 1 month (*, P  0.05 vs. baseline; **, P  0.01 vs. baseline and 1
month).
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bolic homeostasis, including reductions in hormone pro-
duction and increased risk of insulin resistance and im-
paired glucose tolerance (19). An age-related decline in
adropin production could thus contribute to the deterio-
ration of metabolic homeostasis associated with aging.
We also assessed plasma adropin levels throughout the
daytime and after an overnight fast. No circadian-, meal-,
or fasting-related changes were observed, suggesting that
adropin levels are not regulated by acute signals of nutri-
ent intake in humans. It is possible that more prolonged
negative energy balancewill alter plasma adropin levels as
observed for fibroblast growth factor-21, a liver-secreted
hormone that exhibits acute regulation by fasting in mice
but that requires longer-term fasting in humans (20).
In summary, obesity and aging are associated with
lower circulating adropin concentrations in humans.
Analysis of adropin-deficient mice suggests that this pep-
tide hormone is required for metabolic homeostasis, spe-
cifically for maintaining insulin sensitivity and preventing
dyslipidemia and protecting against impaired glucose tol-
erance. In the current study,we observed that low adropin
levels are associated with high fasting TG concentrations,
consistentwith a similar role in humans. In addition, adro-
pin levels increase after RYGB, and this is related to
changes in TG after surgery. Additional studies investi-
gating the impact ofweight changes on adropin regulation
and whether plasma adropin levels predict risk for meta-
bolic disorders such as dyslipidemia and type 2 diabetes
are clearly warranted.
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